AnaptysBio, Inc. (NASDAQ:ANAB) is a biotechnology company focused on developing antibody therapeutics for inflammation and immuno-oncology. The company aims to address unmet medical needs through its innovative approach to drug development. In the competitive landscape, AnaptysBio faces peers like Deciphera Pharmaceuticals, Crinetics Pharmaceuticals, Rhythm Pharmaceuticals, Kura Oncology, and CytomX Therapeutics.

AnaptysBio’s financial performance, particularly its Return on Invested Capital (ROIC) of -26.40%, indicates challenges in generating positive returns from its investments. This negative ROIC, when compared to its Weighted Average Cost of Capital (WACC) of 13.27%, results in a ROIC to WACC ratio of -1.99. This suggests that AnaptysBio is not effectively using its capital to generate returns above its cost of capital.

In comparison, Deciphera Pharmaceuticals has an even lower ROIC of -60.55% and a WACC of 5.15%, leading to a ROIC to WACC ratio of -11.75. This indicates that Deciphera is also struggling significantly to generate returns on its invested capital. Similarly, Crinetics Pharmaceuticals and Rhythm Pharmaceuticals show negative ROICs of -28.74% and -62.80%, respectively, with ROIC to WACC ratios of -5.19 and -3.98, highlighting their challenges in capital efficiency.

Kura Oncology, with a ROIC of -31.40% and a WACC of 6.53%, has a ROIC to WACC ratio of -4.81, further emphasizing the difficulties faced by these companies in generating returns above their cost of capital. However, CytomX Therapeutics stands out with a positive ROIC of 66.72% and a WACC of 9.00%, resulting in a ROIC to WACC ratio of 7.42. This indicates that CytomX is effectively utilizing its capital to generate substantial returns, setting it apart from its peers.